You appear to be offline. Some data may be unavailable until your connection is restored.
Description
AbbVie Inc. is a global specialty biopharmaceutical company that discovers, develops, manufactures and markets medicines for complex and serious diseases, focusing on therapeutic areas such as immunology, oncology, neuroscience, eye care and aesthetics. Its business model relies on a portfolio of patented biologics and small‑molecule drugs—including well‑known products like Humira, Imbruvica and Botox—supported by contract manufacturing services and worldwide commercial operations. Formed in 2012 as a spin‑off from Abbott Laboratories, AbbVie is among the largest biomedical firms by revenue and is a component of major U.S. indices, reflecting a strong market position in the pharmaceutical sector.
Quarterly Earnings
| Quarter | DateReport date | EPSReported EPS |
|---|---|---|
| Q2 FY26 | Jul 30, 2026 | — |
| Q1 FY26 | Apr 29, 2026 | $2.65 |
| Q4 FY25 | Feb 4, 2026 | $2.71 |
| Q3 FY25 | Oct 31, 2025 | $1.86 |
| Q2 FY25 | Jul 31, 2025 | $2.97 |
Stay ahead of ABBV earnings
Get reminders ahead of ABBV's next earnings report, so you always know when results are coming.